Literature DB >> 16227158

In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line.

Johan Kjellström1, Elisabeth Kjellén, Anders Johnsson.   

Abstract

The current study was designed to compare the radiosensitizing effects of oxaliplatin and 5-fluorouracil (5FU) in a human colon cancer cell line. A human colon cancer cell line (S1) was treated with various doses of oxaliplatin, 5FU, radiation, and combinations thereof. Various clinically used schedules were mimicked. 5FU was either incubated during 1 h ("bolus") or 24 h ("continuous infusion"). When combining oxaliplatin and 5FU, an isobologram analysis revealed synergistic effects, regardless of 5FU schedule. The IC(10) and IC(50)-doses for the drugs where then combined with radiotherapy. With equitoxic drug doses (IC(50)), radiosensitization was observed in the following order: oxaliplatin > 5FU 24 h > 5FU 1 h exposure. The degree of potentiation corresponded to approximately 0.8 Gy, 0.7 Gy, and 0.2 Gy, respectively. In this experimental setting, oxaliplatin seemed to be a better radiosensitizer than 5FU, and longer incubation time with 5FU was better than short exposure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227158     DOI: 10.1080/02841860500247552

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  19 in total

1.  Prolonged neutropenia after neoadjuvant radiation therapy and chemotherapy using oxaliplatin and capecitabine for rectal cancer.

Authors:  Daniel C McFarland; William T Leslie
Journal:  Gastrointest Cancer Res       Date:  2011-01

2.  Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model.

Authors:  Tania A Rozgaja Stallons; Amal Saidi; Izabela Tworowska; Ebrahim S Delpassand; Julien J Torgue
Journal:  Mol Cancer Ther       Date:  2019-03-29       Impact factor: 6.261

3.  Gastrointestinal cancer: Light and shade of intrahepatic arterial radiotherapy in mCRC.

Authors:  Josep Tabernero; Ramon Salazar
Journal:  Nat Rev Clin Oncol       Date:  2016-06-14       Impact factor: 66.675

Review 4.  Pharmacotherapy options for locally advanced and advanced cervical cancer.

Authors:  Alfonso Dueñas-González; Lucely Cetina; Jaime Coronel; Déborah Martínez-Baños
Journal:  Drugs       Date:  2010-03-05       Impact factor: 9.546

5.  Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo.

Authors:  Franziska Eckert; Ivan Jelas; Moritz Oehme; Stephan M Huber; Katja Sonntag; Christian Welker; Stephen D Gillies; Wolfgang Strittmatter; Daniel Zips; Rupert Handgretinger; Karin Schilbach
Journal:  Oncoimmunology       Date:  2017-04-28       Impact factor: 8.110

6.  Preoperative intensified radiochemotherapy for rectal cancer: experience of a single institution.

Authors:  Francesco Dionisi; Daniela Musio; Nicola Raffetto; Giovanni Codacci-Pisanelli; Eva Iannacone; Rossella Caiazzo; Enzo Banelli
Journal:  Int J Colorectal Dis       Date:  2010-11-25       Impact factor: 2.571

Review 7.  Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data.

Authors:  Susan Shamimi-Noori; Carin F Gonsalves; Colette M Shaw
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

Review 8.  Rectal cancer treatment: improving the picture.

Authors:  Juan A Diaz-Gonzalez; Leire Arbea; Javier Aristu
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

9.  The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay.

Authors:  Adalsteinn Gunnlaugsson; Per Nilsson; Elisabeth Kjellén; Anders Johnsson
Journal:  Radiat Oncol       Date:  2009-12-09       Impact factor: 3.481

10.  Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice.

Authors:  Therese Seierstad; Sigurd Folkvord; Kathrine Røe; Kjersti Flatmark; Arne Skretting; Dag Rune Olsen
Journal:  Neoplasia       Date:  2007-05       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.